133 related articles for article (PubMed ID: 8012972)
41. Anticarcinogenic actions of tributyrin, a butyric acid prodrug.
Heidor R; Ortega JF; de Conti A; Ong TP; Moreno FS
Curr Drug Targets; 2012 Dec; 13(14):1720-9. PubMed ID: 23140283
[TBL] [Abstract][Full Text] [Related]
42. Retinoic acid inhibits sodium butyrate-induced monocytic differentiation of HL60 cells while synergistically inducing granulocytoid differentiation.
He RY; Breitman TR
Eur J Haematol; 1991 Feb; 46(2):93-100. PubMed ID: 1995327
[TBL] [Abstract][Full Text] [Related]
43. Tributyrin, a stable and rapidly absorbed prodrug of butyric acid, enhances antiproliferative effects of dihydroxycholecalciferol in human colon cancer cells.
Gaschott T; Steinhilber D; Milovic V; Stein J
J Nutr; 2001 Jun; 131(6):1839-43. PubMed ID: 11385076
[TBL] [Abstract][Full Text] [Related]
44. Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: efficacy of tributyrin, a butyric acid prodrug.
Kuroiwa-Trzmielina J; de Conti A; Scolastici C; Pereira D; Horst MA; Purgatto E; Ong TP; Moreno FS
Int J Cancer; 2009 Jun; 124(11):2520-7. PubMed ID: 19195022
[TBL] [Abstract][Full Text] [Related]
45. [Effect of alpha interferon on erythroid differentiation of a human leukemia cell line K562 (S)].
Cioè L; Meo P; Rossi GB
Ann Ist Super Sanita; 1982; 18(3):405-7. PubMed ID: 6964820
[No Abstract] [Full Text] [Related]
46. Antitumor activity of tributyrin in murine melanoma model.
Giermasz A; Nowis D; Jalili A; Basak G; Marczak M; Makowski M; Czajka A; Młynarczuk I; Hoser G; Stok osa T; Lewandowski S; Jakóbisiak M
Cancer Lett; 2001 Mar; 164(2):143-8. PubMed ID: 11179828
[TBL] [Abstract][Full Text] [Related]
47. Approaches to more effective induction of cytodifferentiation of transformed cells and potential for cancer treatment.
Marks PA; Rifkind RA
Rinsho Ketsueki; 1990 Apr; 31(4):401-8. PubMed ID: 2199696
[TBL] [Abstract][Full Text] [Related]
48. [Protective activity of monoacetone glucose 3-butyrate, prodrug of n-butyric acid, against the fatal effect of encephalomyocarditis virus in mice].
Pouillart P; Cerutti I; Ronco G; Villa P; Chany C
C R Acad Sci III; 1992; 314(2):49-54. PubMed ID: 1313734
[TBL] [Abstract][Full Text] [Related]
49. Tributyrin plus all-trans-retinoic acid efficiently induces fetal hemoglobin expression in human erythroleukemia cells.
Witt O; Schmejkal S; Pekrun A
Am J Hematol; 2000 Aug; 64(4):319-21. PubMed ID: 10911389
[TBL] [Abstract][Full Text] [Related]
50. Geranylgeranylacetone used as an antiulcer agent is a potent inducer of differentiation of various human myeloid leukemia cell lines.
Sakai I; Tanaka T; Osawa S; Hashimoto S; Nakaya K
Biochem Biophys Res Commun; 1993 Mar; 191(3):873-9. PubMed ID: 8466527
[TBL] [Abstract][Full Text] [Related]
51. The linking of anticancer drugs, cell cycle blocks, and differentiation: implications in the search for antineoplastic drugs.
Dinnen RD; Ebisuzaki K
Leuk Res; 1992; 16(5):491-5. PubMed ID: 1625475
[TBL] [Abstract][Full Text] [Related]
52. Piperazine derivatives of butyric acid as differentiating agents in human leukemic cells.
Gillet R; Jeannesson P; Sefraoui H; Arnould-Guérin ML; Kirkiacharian S; Jardillier JC; Pieri F
Cancer Chemother Pharmacol; 1998; 41(3):252-5. PubMed ID: 9443644
[TBL] [Abstract][Full Text] [Related]
53. Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity.
Nudelman A; Rephaeli A
J Med Chem; 2000 Jul; 43(15):2962-6. PubMed ID: 10956204
[TBL] [Abstract][Full Text] [Related]
54. Butyric acid and tributyrin induce apoptosis in human hepatic tumour cells.
Watkins SM; Carter LC; Mak J; Tsau J; Yamamoto S; German JB
J Dairy Res; 1999 Nov; 66(4):559-67. PubMed ID: 10612054
[TBL] [Abstract][Full Text] [Related]
55. Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrug.
Rabizadeh E; Shaklai M; Nudelman A; Eisenbach L; Rephaeli A
FEBS Lett; 1993 Aug; 328(3):225-9. PubMed ID: 8348968
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2,2-trichloroethyl)phosphate derivatives of 5-fluoro-2'-deoxyuridine and 2',5-difluoro-2'-deoxyuridine as potential dual action anticancer prodrugs.
Xia Z; Wiebe LI; Miller GG; Knaus EE
Arch Pharm (Weinheim); 1999 Aug; 332(8):286-94. PubMed ID: 10489539
[TBL] [Abstract][Full Text] [Related]
57. Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases.
Nudelman A; Gnizi E; Katz Y; Azulai R; Cohen-Ohana M; Zhuk R; Sampson SR; Langzam L; Fibach E; Prus E; Pugach V; Rephaeli A
Eur J Med Chem; 2001 Jan; 36(1):63-74. PubMed ID: 11231050
[TBL] [Abstract][Full Text] [Related]
58. Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells.
Leder A; Leder P
Cell; 1975 Jul; 5(3):319-22. PubMed ID: 1056809
[TBL] [Abstract][Full Text] [Related]
59. Effect of butyrate analogues on proliferation and differentiation in human neuroblastoma cell lines.
Rocchi P; Ferreri AM; Magrini E; Perocco P
Anticancer Res; 1998; 18(2A):1099-103. PubMed ID: 9615772
[TBL] [Abstract][Full Text] [Related]
60. Butyrate-induced differentiation in leukemic myeloid cells - in-vitro and in-vivo studies.
Rephaeli A; Nordenberg J; Aviram A; Rabizadeh E; Zimra Y; Nudelman A; Novogrodsky A; Shaklai M
Int J Oncol; 1994 Jun; 4(6):1387-91. PubMed ID: 21567067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
